Table 3 CKD-MBD parameters and phosphate binder pill burden at baseline and during sucroferric oxyhydroxide follow-up (Q1 to Q4) in the overall study cohort (N = 1096)

Serum phosphate, mmol/L

1.88 ± 0.36

1.77 ± 0.41^***

1.70 ± 0.40^***

1.70 ± 0.42^***

1.69 ± 0.42^***

Serum PTH, pmol/L

47.5 ± 46.7

48.8 ± 46.0

48.4 ± 47.2

50.6 ± 52.7

52.1 ± 51.8

Serum calcium, mmol/L

2.24 ± 0.16

2.23 ± 0.17^*

2.24 ± 0.17

2.24 ± 0.17

2.24 ± 0.16

Total phosphate binder pill consumption, pills/day

6.3 ± 9.0

5.1 ± 7.6

5.0 ± 5.4

5.3 ± 5.6

5.2 ± 5.5

SFOH pill consumption, pills/day

N/A

2.3 ± 1.4

2.5 ± 1.5

2.6 ± 1.5

2.6 ± 1.5

SFOH dose, mg/day

N/A

1172 ± 718

1236 ± 773

1285 ± 770

1308 ± 765

Number of patients receiving cinacalcet, n (%)

355 (32.6)

357 (36.9)

267 (36.2)

200 (37.3)

148 (39.2)

Number of patients receiving vitamin D analogs, n (%)

426 (39.1)

372 (38.4)

293 (39.7)

223 (41.6)

158 (41.8)